The FDA has granted breakthrough device designation to the ACR-368 OncoSignature assay for use in endometrial cancer.

The detected neoplasms were of neuroendocrine lineage in half of the patients, including SCLC (four), and neuroendocrine tumours of the pancreas (three), oesophagus (one) and endometrium (one). Other ...

jhmi.edu Objective Although pancreatic ductal adenocarcinoma is considered a rapidly progressive disease, mathematical models estimate that it takes many years for an initiating pancreatic cancer cell ...

Method: Two-sample Mendelian randomization was employed to probe the causal association between lipid traits and endometrial carcinoma. Drug-target Mendelian randomization was also utilized to ...

It is well recognized that, in many cases, endometrial carcinoma is a well differentiated tumor bearing a marked resemblance to the parent organ tissue. Elton 14 noted in such tumors appearing ...

1Department of Thoracic Surgery, Nanjing Medical University Affiliated Cancer Hospital & Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research, Nanjing, P. R. China. 2Jiangsu Key Laboratory ...

The Keytruda plus Lenvima combination is currently approved in the United States, Europe, Japan and other countries for treating certain types of advanced endometrial carcinoma and advanced renal cell ...

Thin Endometrium Explained: The endometrium is the innermost lining of the uterus that plays a crucial role in the reproductive process. Every month, the endometrial lining thickens in preparation ...

known as advanced renal cell carcinoma, and certain types of advanced endometrial carcinoma — a type of uterine cancer. The safety profile of the combination was consistent with that observed in ...

1 The Keytruda plus Lenvima combination has been approved for advanced renal cell carcinoma and for patients with advanced endometrial carcinoma that is mismatch repair proficient or not ...

Keytruda and Lenvima are approved together for patients with advanced renal cell carcinoma and certain types of endometrial carcinoma. The companies are also studying the combo in hepatocellular ...